Monoclonal antibodies and other biologic agents in the treatment of asthma

mAbs

Volumn 1, Issue 3, 2009, Pages 237-246

  Long, Aidan A ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Airway inflammation; Cytokine blockers; Dendritic cell; IgE; Immunomodulators; Monoclonal antibodies; Omalizumab; T H1 cells; T H2 cells

Indexed keywords

ADALIMUMAB; ALTRAKINCEPT; CALCINEURIN; CORTICOSTEROID; DACLIZUMAB; EFALIZUMAB; ETANERCEPT; IMMUNOGLOBULIN E; INFLIXIMAB; INTERLEUKIN 13 ANTIBODY; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 9; KELIXIMAB; LUMILIXIMAB; MEDI 528; MEPOLIZUMAB; MONOCLONAL ANTIBODY; OMALIZUMAB; PASCOLIZUMAB; PITAKINRA; PLACEBO; REZLIZUMAB; STEROID; TACROLIMUS; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR 9 AGONIST; TOLL LIKE RECEPTOR AGONIST; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABSENCE OF SIDE EFFECTS; ADJUVANT THERAPY; ALLERGIC ASTHMA; ALLERGIC RHINITIS; ALLERGY; ANGIONEUROTIC EDEMA; ASTHMA; ATOPIC DERMATITIS; BRONCHOPULMONARY ASPERGILLOMA; CELL ACTIVATION; CELL HETEROGENEITY; CELL THERAPY; DENDRITIC CELL; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG WITHDRAWAL; FORCED EXPIRATORY VOLUME; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOTHERAPY; KIDNEY ALLOGRAFT REJECTION; LOW DRUG DOSE; LYMPHOCYTE PROLIFERATION; NONHUMAN; PATHOGENESIS; PHENOTYPE; REVIEW; RHINOCONJUNCTIVITIS; SINGLE DRUG DOSE; T LYMPHOCYTE; TH17 CELL; TH2 CELL; TREATMENT INDICATION; URTICARIA;

ANIMALS; ANTIBODIES, MONOCLONAL; ASTHMA; BIOLOGICAL FACTORS; CYTOKINES; DENDRITIC CELLS; HUMANS; IMMUNOGLOBULIN E; IMMUNOMODULATION; TH2 CELLS; TOLL-LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77951535660     PISSN: 19420862     EISSN: None     Source Type: Journal    
DOI: 10.4161/mabs.1.3.8352     Document Type: Review

References (99)

1. Busse WW, Lemanske RF Jr. Asthma. N Engl J Med 2001; 344:350-362
2. Pascual RM, Peters SP. Airway remodeling contributes to the progressive loss of lung function in asthma: an overview. J Allergy Clin Immunol 2005; 116:477-486 (Pubitemid 41267113)
3. Galli SJ, Tsai M, Piliponsky AM. The development of allergic inflammation. Nature 2008; 454:445-454
4. Holgate ST, Polosa R. Treatment strategies for allergy and asthma. Nat Rev Immunol 2008; 8:218-230
5. Schleimer RP, Kato A, Kern R, Kuperman D, Avila PC. Epithelium: at the interface of innate and adaptive immune responses. J Allergy Clin Immunol 2007; 120:1279-1284 (Pubitemid 350216601)
6. Lambrecht BN. Lung dendritic cells: targets for therapy in allergic disease. Curr Mol Med 2008; 8:393-400.
7. Maurer D, Ebner C, Reininger B, Fiebiger E, Kraft D, Kinet JP, et al. The high affinity IgE receptor (FcepsilonRI) mediates IgE-dependent allergen presentation. J Immunol 1995; 154:6285-6290
8. Maurer D, Ebner C, Reininger B, Petzelbauer P, Fiebiger E, Stingl G. Mechanisms of FcepsilonRI-IgE-facilitated allergen presentation by dendritic cells. Adv Exp Med Biol 1997; 417:175-178 (Pubitemid 27427739)
9. Holt PG, Upham JW. The role of dendritic cells in asthma. Curr Opin Allergy Clin Immunol 2004; 4:39-44.
10. Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 2006; 5:471-484 (Pubitemid 44136959)
11. Bhattacharjee RN, Akira S. Modifying toll-like receptor 9 signaling for therapeutic use. Mini Rev Med Chem 2006; 6:287-291
12. Hayashi T, Raz E. TLR9-based immunotherapy for allergic disease. Am J Med 2006; 119:897.
13. Kline JN. Eat dirt: CpG DNA and immunomodulation of asthma. Proc Am Thorac Soc 2007; 4:283-288 (Pubitemid 47036450)
14. Creticos PS, Schroeder JT, Hamilton RG, Balcer-Whaley SL, Khattignavong AP, Lindblad R, et al. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med 2006; 355:1445-1455 (Pubitemid 44511559)
15. Tulic MK, Fiset PO, Christodoulopoulos P, Vaillancourt P, Desrosiers M, Lavigne F, et al. Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response. J Allergy Clin Immunol 2004; 113:235-241 (Pubitemid 38210543)
16. Simons FE, Shikishima Y, Van Nest G, Eiden JJ, HayGlass KT. Selective immune redirection in humans with ragweed allergy by injecting Amb a 1 linked to immunostimulatory DNA. J Allergy Clin Immunol 2004; 113:1144-1151 (Pubitemid 38857998)
17. Soumelis V, Reche PA, Kanzler H, Yuan W, Edward G, Homey B, et al. Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat Immunol 2002; 3:673-680 (Pubitemid 34752477)
18. Gilliet M, Soumelis V, Watanabe N, Hanabuchi S, Antonenko S, de Waal-Malefyt R, et al. Human dendritic cells activated by TSLP and CD40L induce proallergic cytotoxic T cells. J Exp Med 2003; 197:1059-1063 (Pubitemid 36523204)
19. Allakhverdi Z, Comeau MR, Jessup HK, Yoon BR, Brewer A, Chartier S, et al. Thymic stromal lymphopoietin is released by human epithelial cells in response to microbes, trauma, or inflammation and potently activates mast cells. J Exp Med 2007; 204:253-258 (Pubitemid 46294541)
20. Komai-Koma M, Xu D, Li Y, McKenzie AN, McInnes IB, Liew FY. IL-33 is a chemoattractant for human Th2 cells. Eur J Immunol 2007; 37:2779-2786 (Pubitemid 47578297)
21. Pecaric-Petkovic T, Didichenko SA, Kaempfer S, Spiegl N, Dahinden CA. Human basophils and eosinophils are the direct target leukocytes of the novel IL-1-family member IL-33. Blood 2009; 113:1526-1534
22. Bielekova B, Catalfamo M, Reichert-Scrivner S, Packer A, Cerna M, Waldmann TA, et al. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci USA 2006; 103:5941-5946
23. + regulatory T-cell pool is present in renal transplant recipients. Am J Transplant 2007; 7:249-255
24. Pillai V, Ortega SB, Wang CK, Karandikar NJ. Transient regulatory T-cells: a state attained by all activated human T-cells. Clin Immunol 2007; 123:18-29. (Pubitemid 46401504)
25. Busse WW, Israel E, Nelson HS, Baker JW, Charous BL, Young DY, et al. Daclizumab Improves Asthma Control in Patients with Moderate to Severe Persistent Asthma. Am J Respir Crit Care Med 2008; 178:1002-1008
26. Kon OM, Sihra BS, Compton CH, Leonard TB, Kay AB, Barnes NC. Randomised, dose-ranging, placebo-controlled study of chimeric antibody to CD4 (keliximab) in chronic severe asthma. Lancet 1998; 352:1109-1113 (Pubitemid 28448517)
27. Kon OM, Sihra BS, Loh LC, Barkans J, Compton CH, Barnes NC, et al. The effects of an anti-CD4 monoclonal antibody, keliximab, on peripheral blood CD4+ T-cells in asthma. Eur Respir J 2001; 18:45-52. (Pubitemid 32717430)
28. Corrigan CJ, Hartnell A, Kay AB. T lymphocyte activation in acute severe asthma. Lancet 1988; 1:1129-1132 (Pubitemid 18120681)
29. Nakajima H, Takatsu K. Role of cytokines in allergic airway inflammation. Int Arch Allergy Immunol 2007; 142:265-273 (Pubitemid 46425806)
30. Borish LC, Nelson HS, Corren J, Bensch G, Busse WW, Whitmore JB, et al. Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J Allergy Clin Immunol 2001; 107:963-970 (Pubitemid 32523334)
31. Borish LC, Nelson HS, Lanz MJ, Claussen L, Whitmore JB, Agosti JM, et al. Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebocontrolled trial. Am J Respir Crit Care Med 1999; 160:1816-1823 (Pubitemid 30004681)
32. Adcock IM, Caramori G, Chung KF. New targets for drug development in asthma. Lancet 2008; 372:1073-1087
33. Andrews AL, Holloway JW, Holgate ST, Davies DE. IL-4 receptor alpha is an important modulator of IL-4 and IL-13 receptor binding: implications for the development of therapeutic targets. J Immunol 2006; 176:7456-7461 (Pubitemid 43849048)
34. Hart TK, Blackburn MN, Brigham-Burke M, Dede K, Al-Mahdi N, Zia-Amirhosseini P, et al. Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized antiinterleukin- 4 antibody with therapeutic potential in asthma. Clin Exp Immunol 2002; 130:93-100.
35. Rothenberg ME, Hogan SP. The eosinophil. Annu Rev Immunol 2006; 24:147-174
36. Doherty T, Broide D. Cytokines and growth factors in airway remodeling in asthma. Curr Opin Immunol 2007; 19:676-680 (Pubitemid 350236803)
37. Dent LA, Strath M, Mellor AL, Sanderson CJ. Eosinophilia in transgenic mice expressing interleukin 5. J Exp Med 1990; 172:1425-1431 (Pubitemid 20366218)
38. Lee JJ, McGarry MP, Farmer SC, Denzler KL, Larson KA, Carrigan PE, et al. Interleukin-5 expression in the lung epithelium of transgenic mice leads to pulmonary changes pathognomonic of asthma. J Exp Med 1997; 185:2143-2156 (Pubitemid 27265998)
39. Van Oosterhout AJ, Ladenius AR, Savelkoul HF, Van Ark I, Delsman KC, Nijkamp FP. Effect of anti-IL-5 and IL-5 on airway hyperreactivity and eosinophils in guinea pigs. Am Rev Respir Dis 1993; 147:548-552 (Pubitemid 23072640)
40. Akutsu I, Kojima T, Kariyone A, Fukuda T, Makino S, Takatsu K. Antibody against interleukin-5 prevents antigen-induced eosinophil infiltration and bronchial hyperreactivity in the guinea pig airways. Immunol Lett 1995; 45:109-116
41. Leckie MJ, ten Brinke A, Khan J, Diamant Z, O'Connor BJ, Walls CM, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000; 356:2144-2148
42. Kips JC, O'Connor BJ, Langley SJ, Woodcock A, Kerstjens HA, Postma DS, et al. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am J Respir Crit Care Med 2003; 167:1655-1659 (Pubitemid 36760679)
43. Flood-Page P, Swenson C, Faiferman I, Matthews J, Williams M, Brannick L, et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med 2007; 176:1062-1071 (Pubitemid 350223751)
44. Flood-Page P, Menzies-Gow A, Phipps S, Ying S, Wangoo A, Ludwig MS, et al. Anti- IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest 2003; 112:1029-1036 (Pubitemid 38056318)
45. Liu LY, Sedgwick JB, Bates ME, Vrtis RF, Gern JE, Kita H, et al. Decreased expression of membrane IL-5 receptor alpha on human eosinophils: II. IL-5 down-modulates its receptor via a proteinase-mediated process. J Immunol 2002; 169:6459-6466 (Pubitemid 36903496)
46. Liu LY, Sedgwick JB, Bates ME, Vrtis RF, Gern JE, Kita H, et al. Decreased expression of membrane IL-5 receptor alpha on human eosinophils: I. Loss of membrane IL-5 receptor alpha on airway eosinophils and increased soluble IL-5 receptor alpha in the airway after allergen challenge. J Immunol 2002; 169:6452-6458
47. Plotz SG, Simon HU, Darsow U, Simon D, Vassina E, Yousefi S, et al. Use of an antiinterleukin- 5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. N Engl J Med 2003; 349:2334-2339 (Pubitemid 37521232)
48. Garrett JK, Jameson SC, Thomson B, Collins MH, Wagoner LE, Freese DK, et al. Antiinterleukin- 5 (mepolizumab) therapy for hypereosinophilic syndromes. J Allergy Clin Immunol 2004; 113:115-119 (Pubitemid 38096170)
49. Klion AD, Law MA, Noel P, Kim YJ, Haverty TP, Nutman TB. Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome. Blood 2004; 103:2939-2941 (Pubitemid 38451664)
50. Stein ML, Collins MH, Villanueva JM, Kushner JP, Putnam PE, Buckmeier BK, et al. Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis. J Allergy Clin Immunol 2006; 118:1312-1319 (Pubitemid 44872890)
51. Rothenberg ME, Klion AD, Roufosse FE, Kahn JE, Weller PF, Simon HU, et al. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med 2008; 358:1215-1228
52. Nair P, Pizzichini MMM, Kjarsgaard M, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009; 360:985-993
53. Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009; 360:973-984
54. Wenzel SE. Eosinophils in Asthma-Closing the Loop or Opening the Door? N Engl J Med 2009; 360:1026-1028
55. Hershey GK. IL-13 receptors and signaling pathways: an evolving web. J Allergy Clin Immunol 2003; 111:677-690 (Pubitemid 36470232)
56. Wills-Karp M. Interleukin-13 in asthma pathogenesis. Immunol Rev 2004; 202:175-190
57. Wills-Karp M, Luyimbazi J, Xu X, Schofield B, Neben TY, Karp CL, et al. Interleukin-13: central mediator of allergic asthma. Science 1998; 282:2258-2261 (Pubitemid 29004074)
58. Wynn TA. IL-13 effector functions. Annu Rev Immunol 2003; 21:425-456
59. Grunig G, Warnock M, Wakil AE, Venkayya R, Brombacher F, Rennick DM, et al. Requirement for IL-13 independently of IL-4 in experimental asthma. Science 1998; 282:2261-2263 (Pubitemid 29004075)
60. Yang G, Volk A, Petley T, Emmell E, Giles-Komar J, Shang X, et al. Anti-IL-13 monoclonal antibody inhibits airway hyperresponsiveness, inflammation and airway remodeling. Cytokine 2004; 28:224-232 (Pubitemid 39573497)
61. Wenzel S, Wilbraham D, Fuller R, Getz EB, Longphre M. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet 2007; 370:1422-1431 (Pubitemid 47576168)
62. Bryan SA, O'Connor BJ, Matti S, Leckie MJ, Kanabar V, Khan J, et al. Effects of recombinant human interleukin-12 on eosinophils, airway hyper-responsiveness and the late asthmatic response. Lancet 2000; 356:2149-2153 (Pubitemid 32047953)
63. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005; 6:1123-1132 (Pubitemid 41541790)
64. Mills KH. Induction, function and regulation of IL-17-producing T cells. Eur J Immunol 2008; 38:2636-2649
65. Wang YH, Liu YJ. The IL-17 cytokine family and their role in allergic inflammation. Curr Opin Immunol 2008.
66. McKinley L, Alcorn JF, Peterson A, Dupont RB, Kapadia S, Logar A, et al. TH17 cells mediate steroid-resistant airway inflammation and airway hyperresponsiveness in mice. J Immunol 2008; 181:4089-4097
67. Ballantyne SJ, Barlow JL, Jolin HE, Nath P, Williams AS, Chung KF, et al. Blocking IL-25 prevents airway hyperresponsiveness in allergic asthma. J Allergy Clin Immunol 2007; 120:1324-1331 (Pubitemid 350216590)
68. Wang YH, Angkasekwinai P, Lu N, Voo KS, Arima K, Hanabuchi S, et al. IL-25 augments type 2 immune responses by enhancing the expansion and functions of TSLPDC- activated Th2 memory cells. J Exp Med 2007; 204:1837-1847 (Pubitemid 47236321)
69. Fahy JV, Fleming HE, Wong HH, Liu JT, Su JQ, Reimann J, et al. The effect of an anti- IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 1997; 155:1828-1834 (Pubitemid 27256105)
70. Djukanovic R, Wilson SJ, Kraft M, Jarjour NN, Steel M, Chung KF, et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med 2004; 170:583-593 (Pubitemid 39202198)
71. Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001; 108:184-190 (Pubitemid 32735398)
72. Soler M, Matz J, Townley R, Buhl R, O'Brien J, Fox H, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001; 18:254-261 (Pubitemid 32776398)
73. Bousquet J, Cabrera P, Berkman N, Buhl R, Holgate S, Wenzel S, et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2005; 60:302-308 (Pubitemid 40293345)
74. Corren J, Casale T, Deniz Y, Ashby M. Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma. J Allergy Clin Immunol 2003; 111:87-90. (Pubitemid 36143296)
75. Okubo K, Nagakura T. Anti-IgE antibody therapy for Japanese cedar pollinosis: omalizumab update. Allergol Int 2008; 57:205-209
76. Verbruggen K, Van Cauwenberge P, Bachert C. Anti-IgE for the treatment of allergic rhinitis-and eventually nasal polyps? Int Arch Allergy Immunol 2009; 148:87-98.
77. Stock P, Rolinck-Werninghaus C, Wahn U, Hamelmann E. The role of anti-IgE therapy in combination with allergen specific immunotherapy for seasonal allergic rhinitis. BioDrugs 2007; 21:403-410 (Pubitemid 350145448)
78. Kopp MV, Hamelmann E, Zielen S, Kamin W, Bergmann KC, Sieder C, et al. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma. Clin Exp Allergy 2009; 39:271-279
79. Spector SL, Tan RA. Therapeutic alternatives for chronic urticaria: additional reports on omalizumab. Ann Allergy Asthma Immunol 2008; 101:647.
80. Kaplan AP, Joseph K, Maykut RJ, Geba GP, Zeldin RK. Treatment of chronic autoimmune urticaria with omalizumab. J Allergy Clin Immunol 2008; 122:569-573
81. Godse KV. Omalizumab in severe chronic urticaria. Indian J Dermatol Venereol Leprol 2008; 74:157-158
82. Spector SL, Tan RA. Omalizumab also successful in chronic urticaria. J Allergy Clin Immunol 2008; 121:784-785 (Pubitemid 351323863)
83. Andres C, Belloni B, Mempel M, Ring J. Omalizumab for patients with severe and therapy-refractory atopic eczema? Curr Allergy Asthma Rep 2008; 8:179-180
84. Sheinkopf LE, Rafi AW, Do LT, Katz RM, Klaustermeyer WB. Efficacy of omalizumab in the treatment of atopic dermatitis: a pilot study. Allergy Asthma Proc 2008; 29:530-537
85. Kanu A, Patel K. Treatment of allergic bronchopulmonary aspergillosis (ABPA) in CF with anti-IgE antibody (omalizumab). Pediatr Pulmonol 2008; 43:1249-1251
86. Zirbes JM, Milla CE. Steroid-sparing effect of omalizumab for allergic bronchopulmonary aspergillosis and cystic fibrosis. Pediatr Pulmonol 2008; 43:607-610 (Pubitemid 351813015)
87. Giavina-Bianchi P, Giavina-Bianchi M, Agondi R, Kalil J. Omalizumab and Churg- Strauss syndrome. J Allergy Clin Immunol 2008; 122:217-218
88. Pabst S, Tiyerili V, Grohe C. Apparent response to anti-IgE therapy in two patients with refractory "forme fruste" of Churg-Strauss syndrome. Thorax 2008; 63:747-748
89. Leynadier F, Doudou O, Gaouar H, Le Gros V, Bourdeix I, Guyomarch-Cocco L, et al. Effect of omalizumab in health care workers with occupational latex allergy. J Allergy Clin Immunol 2004; 113:360-361 (Pubitemid 38210566)
90. Poole JA, Meng J, Reff M, Spellman MC, Rosenwasser LJ. Anti-CD23 monoclonal antibody, lumiliximab, inhibited allergen-induced responses in antigen-presenting cells and T cells from atopic subjects. J Allergy Clin Immunol 2005; 116:780-788 (Pubitemid 41400542)
91. Brightling C, Berry M, Amrani Y. Targeting TNFalpha: a novel therapeutic approach for asthma. J Allergy Clin Immunol 2008; 121:5-10.
92. Howarth PH, Babu KS, Arshad HS, Lau L, Buckley M, McConnell W, et al. Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax 2005; 60:1012-1018 (Pubitemid 41705469)
93. Thomas PS, Heywood G. Effects of inhaled tumour necrosis factor alpha in subjects with mild asthma. Thorax 2002; 57:774-778 (Pubitemid 34984975)
94. Silvestri M, Bontempelli M, Giacomelli M, Malerba M, Rossi GA, Di Stefano A, et al. High serum levels of tumour necrosis factor-alpha and interleukin-8 in severe asthma: markers of systemic inflammation? Clin Exp Allergy 2006; 36:1373-1381
95. Berry MA, Hargadon B, Shelley M, Parker D, Shaw DE, Green RH, et al. Evidence of a role of tumor necrosis factor alpha in refractory asthma. N Engl J Med 2006; 354:697-708. (Pubitemid 43247140)
96. Morjaria J, Chauhan A, Bobu K, Mehta R, Smith S, North M. Assessment of a soluble TNFalpha fusion protein (etanercept) as a novel therapeutic agent for severe refractory asthma. Proc Am Thorac Soc 2006; 3:16.
97. Morjaria JB, Chauhan AJ, Babu KS, Polosa R, Davies DE, Holgate ST. The role of a soluble TNFalpha receptor fusion protein (etanercept) in corticosteroid refractory asthma: a double blind, randomised, placebo controlled trial. Thorax 2008; 63:584-591 (Pubitemid 351969250)
98. Erin EM, Leaker BR, Nicholson GC, Tan AJ, Green LM, Neighbour H, et al. The effects of a monoclonal antibody directed against tumor necrosis factor-alpha in asthma. Am J Respir Crit Care Med 2006; 174:753-762 (Pubitemid 44511656)
99. Gauvreau GM, Becker AB, Boulet LP, Chakir J, Fick RB, Greene WL, et al. The effects of an anti-CD11a mAb, efalizumab, on allergen-induced airway responses and airway inflammation in subjects with atopic asthma. J Allergy Clin Immunol 2003; 112:331-338 (Pubitemid 36981373)